Skip to main content
Premium Trial:

Request an Annual Quote

Roche Diagnostics Says Judge Ruled Against Enzo in Diagnostic Case

NEW YORK (GenomeWeb News) - Roche Diagnostics today said that a New York district judge ruled in its favor on key aspects of Enzo Biochem's patent-infringement case against the company.
 
According to Roche, the judge adopted "virtually all" of the interpretations proposed by Roche and its co-parties relating to seven Enzo patents.
 
Enzo earlier this week claimed the judge supported its patent-infringement claims against Affymetrix, Roche, Amersham, PerkinElmer, Sigma Aldrich, Orchid Biosciences, and Molecular Probes.
 
The litigation, first filed in 2002, concerns products and techniques for detecting genetic information in biological samples, such as blood. Enzo claimed Roche's AmpliChip CYP450 Test infringed its patent covering the "soluble signal" and the testing format.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.